Application of direct-acting antiviral agents in perioperative period of liver transplantation for patients with hepatitis C
10.3969/j.issn.1001-5256.2015.12.023
- VernacularTitle:直接抗病毒药物在丙型肝炎肝移植患者围手术期抗病毒治疗中的应用
- Author:
Jing ZHANG
1
;
Xuemin LIU
;
Zhengwen LIU
Author Information
1. Department of Hepatobiliary Surgery, The First Affiliated Hospital of Xi′an Jiaotong University School of Medicine, Xi′an 710061, China
- Publication Type:Research Article
- Keywords:
hepatitis C virus;
liver transplantation;
antiviral agents;
review
- From:
Journal of Clinical Hepatology
2015;31(12):2084-2087
- CountryChina
- Language:Chinese
-
Abstract:
For patients with chronic hepatitis C who undergo liver transplantation, recurrence of hepatitis C virus (HCV) infection after liver transplantation has always been a great challenge in the medical field. With our increased understanding of HCV replication cycle, the appearance of direct-acting antiviral agents (DAAs) has brought new hope to patients who have failed interferon therapy. Based on the latest research advances at home and abroad, this article retrospectively introduces the mechanism of action and the development of DAAs, focuses on the clinical application, therapeutic effects, and potential risks of various regimens with DAAs before and after liver transplantation, and systematically reviews the application of DAAs in the perioperative period of liver transplantation for patients with hepatitis C. The results show that DAAs are safe and effective as perioperative antiviral therapies, and a combination of drugs with different targets is recommended as the antiviral therapy in the perioperative period of liver transplantation for patients with chronic hepatitis C.
